Profile data is unavailable for this security.
About the company
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
- Revenue in CHF (TTM)43.45bn
- Net income in CHF10.79bn
- Incorporated1996
- Employees75.88k
- LocationNovartis AGLichtstrasse 35BASEL 4056SwitzerlandCHE
- Phone+41 613241111
- Fax+41 613247826
- Websitehttps://www.novartis.com/
More ▼
Mergers & acquisitions
| Acquired company | NOVN:SWX since announced | Transaction value |
|---|---|---|
| Avidity Biosciences Inc | 18.95% | 9.99bn |
| Tourmaline Bio Inc | 20.99% | 1.37bn |
| Regulus Therapeutics Inc | 31.41% | 1.62bn |
Data delayed at least 15 minutes, as of Feb 12 2026 16:34 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | 22.72bn | 6.57bn | 149.17bn | 17.60k | 22.97 | 8.55 | 23.01 | 6.57 | 6.78 | 6.78 | 23.46 | 18.23 | 0.499 | 2.05 | 6.31 | -- | 14.42 | 8.03 | 18.05 | 9.82 | 78.84 | 78.01 | 28.91 | 18.13 | 1.31 | 36.91 | -- | 73.41 | 2.40 | 3.58 | 1,672.92 | 133.35 | -- | 3.04 |
| Amgen Inc | 28.36bn | 5.95bn | 152.33bn | 28.00k | 25.76 | 22.82 | 18.87 | 5.37 | 14.23 | 14.23 | 67.84 | 16.06 | 0.4029 | 1.48 | 4.49 | -- | 8.45 | 7.90 | 11.52 | 10.18 | 73.30 | 74.68 | 20.98 | 20.55 | 0.8958 | 18.59 | 0.8631 | 72.99 | 9.95 | 7.65 | 88.53 | 1.20 | 25.03 | 8.27 |
| Merck & Co Inc | 50.17bn | 14.09bn | 228.52bn | 75.00k | 16.40 | -- | 15.84 | 4.56 | 7.28 | 7.28 | 25.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 78.55 | 75.41 | 28.09 | 21.08 | -- | 22.68 | -- | -- | 1.31 | 9.38 | 6.64 | 32.21 | -- | 6.01 |
| AstraZeneca plc | 45.34bn | 7.89bn | 241.96bn | 94.30k | 30.86 | 6.44 | 19.63 | 5.34 | 4.81 | 4.81 | 27.62 | 23.03 | 0.5386 | 1.85 | 4.17 | -- | 9.38 | 5.36 | 12.83 | 7.31 | 81.31 | 80.49 | 17.42 | 11.08 | 0.724 | 10.45 | 0.3781 | 86.73 | 8.63 | 17.15 | 45.34 | 26.19 | 17.77 | 2.37 |
| Novartis | 43.45bn | 10.79bn | 261.22bn | 75.88k | 22.40 | 6.67 | 18.10 | 6.01 | 5.52 | 5.52 | 22.26 | 18.55 | 0.5284 | 2.27 | 6.89 | -- | 13.10 | 11.11 | 17.82 | 14.89 | 75.82 | 74.78 | 24.79 | 26.20 | 0.8868 | 16.89 | 0.4318 | 62.30 | 8.91 | 2.45 | 17.11 | 11.62 | 8.57 | 6.62 |
| Roche Holding AG | 61.52bn | 12.88bn | 289.94bn | 112.77k | 22.24 | 8.40 | 16.87 | 4.71 | 16.04 | 16.04 | 76.61 | 42.49 | 0.6076 | 2.15 | 5.40 | 545,480.30 | 13.63 | 13.69 | 19.85 | 21.13 | 73.62 | 72.22 | 22.43 | 20.80 | 1.12 | 16.42 | 0.4551 | 65.69 | 1.69 | 1.07 | 55.61 | -2.06 | 3.50 | 1.49 |
| AbbVie Inc | 46.03bn | 1.81bn | 301.27bn | 55.00k | 166.67 | -- | 36.28 | 6.55 | 1.33 | 1.33 | 33.68 | -1.49 | 0.4302 | 3.66 | 4.92 | 1,084,436.00 | 1.73 | 5.44 | 2.46 | 7.09 | 71.16 | 68.89 | 4.02 | 13.73 | 0.5992 | 7.60 | 1.04 | 134.96 | 3.71 | 11.11 | -12.07 | -11.58 | 12.03 | 8.00 |
Data as of Feb 12 2026. Currency figures normalised to Novartis AG's reporting currency: Swiss Franc CHF
17.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 07 Jan 2026 | 76.81m | 3.64% |
| UBS Asset Management Switzerland AGas of 06 Jan 2026 | 76.53m | 3.62% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 46.32m | 2.19% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 39.67m | 1.88% |
| Z�rcher Kantonalbank (Investment Management)as of 31 Dec 2025 | 28.48m | 1.35% |
| Geode Capital Management LLCas of 05 Feb 2026 | 24.18m | 1.15% |
| BlackRock Advisors (UK) Ltd.as of 09 Jan 2026 | 22.81m | 1.08% |
| Artisan Partners LPas of 31 Dec 2025 | 18.31m | 0.87% |
| BlackRock Asset Management Deutschland AGas of 09 Jan 2026 | 17.37m | 0.82% |
| GQG Partners LLCas of 31 Oct 2025 | 14.10m | 0.67% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
